News

Sarepta Therapeutics: Beaten Down, But Not Out
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Fierce Pharma23h
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Fierce Pharma2d
Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy
Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...
STAT4d
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular ...
Fintel on MSN2d
Barclays Downgrades Sarepta Therapeutics (SRPT)
Fintel reports that on July 27, 2025, Barclays downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Sarepta Therapeutics: What's Happening With SRPT Stock?
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening financial situation.
Zacks Investment Research on MSN2d
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Wall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results ...